RETINOID RECEPTOR FUNCTION IN SKIN CANCER PROGRESSION
皮肤癌进展中的视黄醇受体功能
基本信息
- 批准号:6173954
- 负责人:
- 金额:$ 10.57万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1998
- 资助国家:美国
- 起止时间:1998-07-01 至 2003-06-03
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Squamous cell carcinoma (SCC) is the most clinically aggressive form of
non-melanoma skin cancer and in spite of aggressive treatment, deeply
invasive SCC lesions recur at a high rate (30 percent). Therefore there
is an urgent need for the development of improved therapeutic and
preventive treatments for this disease. Retinoids are important
modulators of epithelial differentiation and proliferation. Retinoids
are effective in the treatment and prevention of epithelial cancers,
including cutaneous SCC. However the mechanism for this effect is not
well understood. In order to better design chemopreventive therapies
for cutaneous SCC, more information about the mechanism of retinoid
action in this system is needed. Retinoids exert their effects
primarily through nuclear receptors, retinoic acid receptors (RARalpha,
beta and gamma) and retinoid X receptors (RXRalpha, beta and gamma),
members of the steroid hormone receptor superfamily. Retinoid receptor
loss has been correlated with malignancy in several systems, and one
recent study has demonstrated a suppression of RARalpha, RARgamma and
RXRalpha expression in SCCs of patients. This study is based on the
hypothesis that retinoid receptor loss contributes to the malignant
phenotype by rendering epithelial cells resistant to retinoids, which
wold normally suppress carcinogenesis. To test this hypothesis, HaCaT
cells, a spontaneously immortalized, nontumorigenic, keratinocyte-
derived cell line was chose. These cells express the two predominant
retinoid receptors normally found in skin, RARgamma and RXRalpha, and
retain the same differentiation characteristics and response to
retinoids as normal keratinocytes. The HaCaT cells, which are a model
for premalignant cells, will be used to accomplish the following
specific aims: 1.) To create RARgamma null, RXTalpha null and
RARgamma/RXRalpha double null cells by homologous recombination-mediated
gene targeting. 2.) To determine whether loss of receptor expression
results in an altered cell phenotype, specifically with regard to
tumorigenic potential, differentiation capacity and response to
alterations in retinoic acid (RA) levels. 3.) To reexpress the missing
receptor (RARgamma or RXRalpha) in the knockout cell lines by stable
transfection in order to determine whether the putative phenotype
observed is the direct result of the genetic lesion. A somatic cell
gene targeting approach has been successfully by the principle
investigator to analyze retinoid receptor function in F9 embryonal
carcinoma cells. It is expected that the generation of receptor null
HaCaT cells will provide an equally powerful tool for understanding the
role of retinoid receptors in the development of cutaneous SCC, as well
as their role in epidermal differentiation.
鳞状细胞癌(SCC)是临床上最具侵袭性的形式,
非黑色素瘤皮肤癌,尽管积极治疗,
浸润性SCC病变复发率很高(30%)。 因而
迫切需要开发改进的治疗和
预防性治疗这种疾病。 维甲酸很重要
上皮分化和增殖的调节剂。 类视黄醇
有效治疗和预防上皮癌,
包括皮肤SCC。 然而,这种效应的机制不是
很好理解。 为了更好地设计化学预防疗法
对于皮肤SCC,更多关于维甲酸机制的信息
需要在这个系统中采取行动。 类维生素A发挥作用
主要通过核受体,视黄酸受体(RAR α,
β和γ)和类维生素A X受体(RXR α、β和γ),
类固醇激素受体超家族的成员。 类视黄醇受体
在几个系统中,损失与恶性肿瘤相关,
最近的研究表明,抑制RAR α,RAR γ和
患者SCC中RXR α的表达。 本研究基于
假设类维生素A受体丢失有助于恶性肿瘤的发生,
表型通过使上皮细胞对类维生素A具有抗性,
通常抑制致癌作用。 为了验证这一假设,HaCaT
细胞,一种自发永生化的,非肿瘤性的角质形成细胞,
选择衍生的细胞系。 这些细胞表达两种主要的
通常在皮肤中发现的类维生素A受体,RAR γ和RXR α,以及
保持相同的分化特征和反应,
类维生素A作为正常角质形成细胞。 HaCaT细胞是一种
对于癌前细胞,将用于完成以下任务
具体目标:1.)要创建RAR gamma null、RXT alpha null和
同源重组介导的RAR γ/RXR α双无效细胞
基因靶向2.)的情况。为了确定受体表达的缺失
导致改变的细胞表型,特别是关于
致瘤潜力、分化能力和对
维甲酸(RA)水平的变化。3.)第三章重新表达思念
受体(RAR γ或RXR α)在敲除细胞系中的稳定表达
转染以确定推定的表型是否
这是遗传病的直接结果。 体细胞
基因打靶方法已经成功地通过原理
研究人员分析F9胚胎中类维生素A受体功能
癌细胞 预期受体无效的产生
HaCaT细胞将提供一个同样强大的工具来了解
类维生素A受体在皮肤SCC发展中的作用,以及
在表皮分化中的作用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOHN L CLIFFORD其他文献
JOHN L CLIFFORD的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOHN L CLIFFORD', 18)}}的其他基金
Identification of Genes Involved in Bladder Cancer
膀胱癌相关基因的鉴定
- 批准号:
7295774 - 财政年份:2006
- 资助金额:
$ 10.57万 - 项目类别:
Identification of Genes Involved in Bladder Cancer
膀胱癌相关基因的鉴定
- 批准号:
7211280 - 财政年份:2006
- 资助金额:
$ 10.57万 - 项目类别:
RETINOID RECEPTOR FUNCTION IN SKIN CANCER PROGRESSION
皮肤癌进展中的视黄醇受体功能
- 批准号:
2896591 - 财政年份:1998
- 资助金额:
$ 10.57万 - 项目类别:
RETINOID RECEPTOR FUNCTION IN SKIN CANCER PROGRESSION
皮肤癌进展中的视黄醇受体功能
- 批准号:
6513293 - 财政年份:1998
- 资助金额:
$ 10.57万 - 项目类别:
RETINOID RECEPTOR FUNCTION IN SKIN CANCER PROGRESSION
皮肤癌进展中的视黄醇受体功能
- 批准号:
6802658 - 财政年份:1998
- 资助金额:
$ 10.57万 - 项目类别:
RETINOID RECEPTOR FUNCTION IN SKIN CANCER PROGRESSION
皮肤癌进展中的视黄醇受体功能
- 批准号:
2680107 - 财政年份:1998
- 资助金额:
$ 10.57万 - 项目类别:
RETINOID RECEPTOR FUNCTION IN SKIN CANCER PROGRESSION
皮肤癌进展中的视黄醇受体功能
- 批准号:
6376867 - 财政年份:1998
- 资助金额:
$ 10.57万 - 项目类别:
RETINOIC ACID RECEPTOR AND CELLULAR DIFFERENTIATION
视黄酸受体和细胞分化
- 批准号:
2170353 - 财政年份:1995
- 资助金额:
$ 10.57万 - 项目类别:
RETINOIC ACID RECEPTOR AND CELLULAR DIFFERENTIATION
视黄酸受体和细胞分化
- 批准号:
2170354 - 财政年份:1995
- 资助金额:
$ 10.57万 - 项目类别:
RETINOIC ACID RECEPTOR AND CELLULAR DIFFERENTIATION
视黄酸受体和细胞分化
- 批准号:
2467547 - 财政年份:1995
- 资助金额:
$ 10.57万 - 项目类别:
相似海外基金
Hedgehog signalling in T-cell differentiation and function
T 细胞分化和功能中的 Hedgehog 信号传导
- 批准号:
BB/Y003454/1 - 财政年份:2024
- 资助金额:
$ 10.57万 - 项目类别:
Research Grant
Comparative single-cell analysis of disease-derived stem cells to identify the cell fate defect on the cell differentiation trajectory
对疾病来源的干细胞进行比较单细胞分析,以确定细胞分化轨迹上的细胞命运缺陷
- 批准号:
23H02466 - 财政年份:2023
- 资助金额:
$ 10.57万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
The role of cell differentiation in colorectal cancer progression
细胞分化在结直肠癌进展中的作用
- 批准号:
23K06661 - 财政年份:2023
- 资助金额:
$ 10.57万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Dissecting the role of hypoxia in T cell differentiation in cancer
剖析缺氧在癌症 T 细胞分化中的作用
- 批准号:
10578000 - 财政年份:2023
- 资助金额:
$ 10.57万 - 项目类别:
Mechanisms mediating human enteroendocrine cell differentiation and function
介导人肠内分泌细胞分化和功能的机制
- 批准号:
10739834 - 财政年份:2023
- 资助金额:
$ 10.57万 - 项目类别:
TOX-driven CD8 T cell differentiation and dysfunction in tumors
TOX驱动的肿瘤中CD8 T细胞分化和功能障碍
- 批准号:
10586679 - 财政年份:2023
- 资助金额:
$ 10.57万 - 项目类别:
Elucidation of molecular mechanisms of immune cell differentiation of a novel Rab protein in hematopoietic stem cells
阐明造血干细胞中新型Rab蛋白免疫细胞分化的分子机制
- 批准号:
23K16122 - 财政年份:2023
- 资助金额:
$ 10.57万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
New strategies in cell replacement therapies for diabetes: role of USP7 in iPSC and adult organoids beta cell differentiation
糖尿病细胞替代疗法的新策略:USP7 在 iPSC 和成体类器官 β 细胞分化中的作用
- 批准号:
MR/X01813X/1 - 财政年份:2023
- 资助金额:
$ 10.57万 - 项目类别:
Research Grant
Role of alveolar fibroblasts in extracellular matrix organization and alveolar type 1 cell differentiation
肺泡成纤维细胞在细胞外基质组织和肺泡1型细胞分化中的作用
- 批准号:
10731854 - 财政年份:2023
- 资助金额:
$ 10.57万 - 项目类别:
Exhaustive Identification of Essential Genes for Human Taste Cell Differentiation ~Development of a Method for Inducing Differentiation of Taste Buds from ES/iPS Cells~
彻底鉴定人类味觉细胞分化必需基因~开发诱导ES/iPS细胞味蕾分化的方法~
- 批准号:
23K09214 - 财政年份:2023
- 资助金额:
$ 10.57万 - 项目类别:
Grant-in-Aid for Scientific Research (C)